Showing results (351-360 of 396) with videos related to
Sort By:
Pageof 40
Iscience|October 13, 2025
Nucleotide motif-guided selection of plasma microRNA biomarkers in traumaBoyang Ren, Ruoxing Li, Chien-Yu Lin, et al.Human Mutation|September 9, 2011
Novel LOVD databases for hereditary breast cancer and colorectal cancer genes in the Chinese populationMin Pan, Peikuan Cong, Yue Wang, et al.British Journal of Haematology|February 19, 2020
Comparison of efficacy from two different dosing regimens of bortezomib: an exposure-response analysisDolly A Parasrampuria, Jianming He, Liping Zhang, et al.Medrxiv : the Preprint Server for Health Sciences|March 17, 2025
Plasma microRNA biomarkers for multi-organ injury prediction in trauma patientsBoyang Ren, Chien-Yu Lin, Ruoxing Li, et al.Journal of the American Heart Association|February 13, 2024
Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular DiseaseGuillaume Marquis-Gravel, Amanda Stebbins, Lisa M Wruck, et al.Critical Care Medicine|July 14, 2021
Admission Features Associated With Paroxysmal Sympathetic Hyperactivity After Traumatic Brain Injury: A Case-Control StudyJamie E Podell, Serenity S Miller, Matthew N Jaffa, et al.Annals of Clinical and Laboratory Science|December 15, 2011
Microsatellite instability in saliva from patients with hereditary non-polyposis colon cancer and siblings carrying germline mismatch repair gene mutationsPeter Hu, Chang Woo Lee, Jing P Xu, et al.Neurocritical Care|October 26, 2023
Overlapping Physiologic Signs of Sepsis and Paroxysmal Sympathetic Hyperactivity After Traumatic Brain Injury: Exploring A Clinical ConundrumVanessa Rose Salasky, Sancharee Hom Chowdhury, Lujie Karen Chen, et al.The Lancet. Oncology|October 24, 2018
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 studyTadeusz Robak, Jie Jin, Halyna Pylypenko, et al.The New England Journal of Medicine|September 3, 2024
Asundexian versus Apixaban in Patients with Atrial FibrillationJonathan P Piccini, Manesh R Patel, Jan Steffel, et al.Pageof 40